Archives

IgA Nephropathy: Pathogenesis, the Role of APRIL & the 4-Hit Process, & a Patient Case Study
About This Event
IgA Nephropathy: Pathogenesis, the Role of APRIL & the 4-Hit Process, & a Patient Case Study
IgA Nephropathy: Pathogenesis, the Role of APRIL and the 4-Hit Process, and a Patient Case Study – Edgar Lerma, MD
-
- Program Objectives:
- The disease burden and current treatment landscape in IgA Nephropathy
- Risk factors associated with disease progression in a patient case study
- The four-hit process in IgA nephropathy pathogenesis and the role of APRIL
- Program Objectives:
-
- Here you can get an in-depth look at IgAN pathogenesis and the journeys of patients living with IgAN
- Pathogenesis: See the origins of IgAN at the molecular level and how that result sin its progression
- Progression: Journey into the profiles of 3 hypothetical patients to see how their IgAN diagnosis was uncovered, and what’s expected in their prognosis
- Here you can get an in-depth look at IgAN pathogenesis and the journeys of patients living with IgAN
-
- Experience disease state education like never before. Using Apple Vision Pro technology, participants can visually explore:
- The 4-hit pathogenic progress of IgAN
- The role of APRIL in initiating and sustaining kidney injury in IgAN
- Experience disease state education like never before. Using Apple Vision Pro technology, participants can visually explore:
-
- Check out our educational infographics and grab printed copies to take with you
- Learn about our educational tools and treatment summaries
The Capital Grille – Plano
Featuring

Edgar Lerma, MD
University of Illinois at Chicago*
Edgar Lerma, MD, earned his Doctor of Medicine from the University of Santo Tomas Faculty of Medicine and Surgery in Manila, Philippines. He completed Residency Training in Internal Medicine at UIC/Mercy Hospital and Medical Center, where he also served as Chief Resident. He completed a Fellowship in Nephrology and Hypertension at Northwestern Memorial Hospital, the Feinberg School of Medicine at Northwestern University, and the Veterans Administration Lakeside Medical Center in Chicago, Illinois.
Dr Lerma is a Diplomate in the Subspecialty of Nephrology with the American Board of Internal Medicine. He has authored more than 100 peer-reviewed publications and presentations; notable publications include Current Diagnosis & Treatment: Nephrology & Hypertension, Nephrology Secrets, and Henrich’s Principles and Practice of Dialysis. He has peer reviewed and served on editorial boards for numerous journals, and currently is Associate Editor for International Urology and Nephrology, Clinical Reviews in Bone and Mineral Metabolism, and Journal of Clinical Lipidology.
At present, he holds the rank of Clinical Professor of Medicine with the Section of Nephrology at University of Illinois at Chicago. He serves as the Educational Coordinator for Nephrology with UIC/Advocate Christ Medical Center.
In recognition of his clinical work and expertise, Dr Lerma has been elected to Fellowship of the American College of Physicians, Fellowship of the American Society of Nephrology, Fellowship of the American Heart Association/ Council on Kidney in Cardiovascular Disease, Fellowship of the American Society of Hypertension, Fellowship of the National Lipid Association, Fellowship of the National Kidney Foundation, and Fellowship of the American Society of Diagnostic and Interventional Nephrology. He has also been recognized for teaching and has been the recipient of “Subspecialty Teaching Attending Physician of the Year” in 2006 and “Physician Recognition Award for Excellence in Academics” in 2011 from UIC/Advocate Christ Medical Center Internal Medicine Residency Training Program.
Dr Lerma’s research interests include CKD, hypertension, bone and mineral disorders, and dyslipidemias in CKD.

Molly Jansen, PhD
Dr Molly Jansen is a Nephrology Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. covering South Texas. Molly earned her Doctor of Philosophy degree in Biomedical Science from Wake Forest School of Medicine located in Winston-Salem, NC. While in graduate school, Molly worked as a Business Development Intern at Wake Forest Innovations, fostering the collaborative innovation between industry and the faculty and staff of Wake Forest Baptist Medical Center. After graduate school, Molly did a brief Medical Writing Fellowship with Impact Pharmaceutical Services. Prior to joining Otsuka, Molly worked at Reata Pharmaceuticals, Inc. where she helped to oversee the conduct of clinical trials across a variety of therapeutic areas including nephrology, neurology, and pulmonary, which is where she developed her passion for rare disease.

Michael Filsinger, MPA, PA-C
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Michael Filsinger, MPA, PA-C is a Medical Science Liaison at Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Michael earned his Bachelor of Health Care Sciences as well as Master of Physician Assistant at Duquesne University in Pittsburgh, PA. Following his graduate training, Michael went on to complete a Pediatric Surgery Residency at Children’s National Medical Center in Washington, DC Prior to joining Otsuka, Michael spent the last 15 years working in solid organ transplant in Charlotte, NC where he developed a passion for improving the care of patients with renal disease and ESKD.
Edgar Lerma, MD is a speaker for Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Molly Jansen, PhD and Michael Filsinger, MPA, PA-C are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)